| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1871.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Mayo Clinic, Rochester, Minn (D.R.H., K.M.D.); the University of Pittsburgh, Pittsburgh, Pa (F.S., J.M.J., S.F.K.); the University of Utah, Salt Lake City, Utah (R.H.); the University of Pittsburgh Medical Center, Pittsburgh, Pa (H.A.C.); and Rhode Island Hospital, Providence, RI (D.O.W.).
Correspondence to David R. Holmes, Jr, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail dholmes{at}mayo.edu
| Abstract |
|---|
|
|
|---|
Methods and Results This study evaluated whether multivariable mortality models developed during the pre-stent era by New York State, American College of Cardiology (ACC)National Cardiovascular Data Registry, Northern New England Cooperative Group, Cleveland Clinic Foundation, and the University of Michigan are relevant in patients undergoing percutaneous coronary intervention in the 1997 to 1999 National Heart, Lung, and Blood Institute Dynamic Registry. Of 4448 Dynamic Registry patients, 73% received
1 stent and 28% received a IIB/IIIA receptor inhibitor. In-hospital mortality occurred in 64 patients (1.4%). The New York state model predicted mortality in 69 patients (1.5%; 95% confidence bounds [CI], 0.89% to 1.70%); Northern New England predicted mortality in 60 patients (1.3%; 95% CI, 1.0% to 1.7%); and Cleveland Clinic predicted mortality in 76 patients (1.7%; 95% CI, 1.3% to 2.1%). Among high-risk subgroups, with these 3 models, observed and predicted in-hospital mortality rates in general were not different. The other 2 models yielded different results. The University of Michigan predicted fewer deaths (n=47; 1.1%; 95% CI, 0.7% to 1.3%), and the ACC Registry model predicted 603 deaths (13.5%; 95% CI, 12.6% to 14.4%). Using the ACC Registry model, predicted mortality was higher than observed in each subgroup.
Conclusions Application of 5 mortality risk models developed from different data sets to patients undergoing percutaneous coronary intervention in the Dynamic Registry predicted, in 3 models, mortality rates that were not significantly different than those observed. In both high and low risk subgroups, the University of Michigan slightly underpredicted mortality, and the ACC Registry predicted significantly higher mortality than that observed.
Key Words: interventional cardiology coronary disease stents
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Definitions
Any in-hospital death occurring after PCI was considered procedure related. Lesion success was an achievement of residual luminal diameter stenosis of <50% with
20% improvement. Procedural success was defined as at least one successful lesion without in-hospital death, Q-wave infarction, or emergency coronary bypass surgery. Myocardial infarction was defined by evidence of
2 of the following: (1) typical chest pain lasting >20 minutes not relieved by nitroglycerin; (2) serial ECG readings showing new changes in ST-T segments and/or Q-waves in
2 contiguous leads; (3) serum enzyme elevation of creatine kinase-MB >5% of total creatine kinase, total creatine kinase greater than twice the normal value, lactate dehydrogenase (LDH) subtype 1 greater than LDH subtype 2, or troponin >0.2 µg/L; and (4) new wall motion abnormalities. Unstable angina was defined as rest angina, new onset of exertional angina of at least Canadian Cardiovascular Society Classification (CCSC) class III, or recent acceleration of angina with an increase in severity of at least one CCSC class to at least class III.
Single vessel disease was defined as
50% diameter stenosis in the right coronary, the left anterior descending, or the left circumflex artery systems; multivessel disease was defined as
50% stenosis in
2 major epicardial vessels. If the left main coronary artery had
50% stenosis, then 2-vessel disease was present. Left ventricular ejection fraction was recorded when measured at each center per site-specific protocols using angiographic, echocardiographic, and/or radionuclide techniques.
Five previously described multivariable in-hospital mortality models were studied: the New York State (NY State),8,9 the American College of Cardiology (ACC)National Cardiovascular Data Registry (ACC),10 the Northern New England Cooperative Group (Northern New England),2 the Cleveland Clinic Foundation Multicenter (Cleveland Clinic),11 and the University of Michigan consortium (Michigan)12 models. All 5 included similar but not identical clinical, angiographic, and planned procedural variables (Appendix 1).2,812 The NHLBI Dynamic Registry collected all data included in each of the models except use of an intra-aortic balloon pump (NY State, ACC, and Northern New England), hemodynamic instability (NY State), salvage versus elective PCI (ACC), and history of cardiac arrest (Michigan). These variables were set to "no" or the lowest level for all patients. The NHLBI Registry recorded history of renal disease and used this variable as a surrogate for elevated creatinine values, which were not collected.
The NHLBI Registry enrolled 4625 patients from 1997 to 1999. Patients missing lesion data (n=168) or age at baseline (n=9) were excluded. The ACC, Northern New England, and Michigan models were developed using imputed left ventricular ejection fraction data and, thus, missing ejection fraction data (n=1849) was imput using a linear regression model that included sex, race, angina class, prior myocardial infarction, acuteness of PCI, number of significant lesions, presence of total occlusion, renal disease, and history of congestive heart failure, diabetes, and prior CABG. All other missing categorical responses (
1% of data), such as history of heart failure or renal disease, were set to "no" or the lowest level.
Statistical analysis results were presented as either mean±SD or as a percentage of the total. Risk scores from all 5 mortality models were calculated from coefficients derived from the multivariable risk factor equation for in-hospital death.2,812 The probabilities of in-hospital death were then summed to determine an expected number of deaths for the overall NHLBI Registry sample, as well as for low and high-risk patient groups for each specific model. The 95% confidence bounds (CI) around the expected death rate were calculated with the normal approximation to a binomial distribution. Observed versus expected mortality by rank-ordered deciles of risk were plotted (ie, calibration). The relationship between each calculated risk score and in-hospital mortality was examined using logistic regression. Each models goodness-of-fit was assessed using the Hosmer-Lemeshow method,16 and fit was considered adequate (P>0.05). Model discrimination was assessed using the area under the receiver operator curve (ROC), and the area under each ROC curve was compared statistically using the Mann-Whitney test.
| Results |
|---|
|
|
|---|
88% of these patients had an ejection fraction >40%, whereas <1% had an ejection fraction <20%.
|
Although two (32.8%) or three (25%) vessel disease was most common, the majority of revascularization procedures involved a single vessel (88.6%). Stent implantation was common at 73.2%. A glycoprotein IIb/IIIa agent was administered either before or during the procedure in 27.8% of patients.
In-hospital outcomes other than death were also evaluated. Angiographic success (
1 lesion treated successfully) and procedural success were achieved in 96.6% and 95.3% of patients, respectively. Myocardial infarction after PCI occurred in 2.9% of patients; 34 patients required CABG within 24 hours after their index procedure (0.8%).
Sixty-four patients (1.4%) died during hospitalization (Table 2). Three of the risk models accurately predicted this in-hospital mortality, with the observed rate falling within the 95% CI: the NY State model predicted 69 deaths (1.5%; 95% CI, 1.2% to 1.9%); the Northern New England model predicted 60 deaths (1.3%; 95% CI, 1.0% to 1.7%); and the Cleveland Clinic model predicted 76 deaths (1.7%; 95% CI, 1.3% to 2.1%). The Michigan model underestimated mortality in the entire group, predicting only 47 deaths (1.1%; 95% CI, 0.7% to 1.3%). In contrast, the ACC model markedly overestimated mortality, predicting 603 deaths (13.5%; 95% CI, 12.6% to 14.4%).
|
For most subgroups, both high and low risk (Table 2), observed and predicted mortalities were not significantly different for NY State, Northern New England, and Cleveland Clinic models. These models were accurate, not only for high risk patients such as those with acute infarction and shock, but were also very accurate for low-risk patients. In patients without acute infarction, 34 deaths were observed (0.8%); the NY State model predicted 42 (1.0%), Northern New England predicted 34 (0.8%), and Cleveland Clinic predicted 38 (0.9%). The ACC model significantly overestimated in-hospital mortality rates for each subgroup. In general, the Michigan model underestimated mortality, although the significant differences were restricted to the high-risk groups. For example, the Michigan model predicted 26 deaths (0.6%; 95% CI, 0.4% to 0.9%) in patients with no acute infarction. For the patients with shock, the Michigan model significantly underpredicted 16 deaths (21.3%; 95% CI, 12.0% to 30.7%) versus the 26 deaths observed (34.7%).
The relationship between the observed and predicted in-hospital mortality by rank-ordered decile of risk in the entire sample is important. The plots for NY State, Northern New England, and Cleveland Clinic models were similar and show a strong correlation between observed and expected mortality by risk decile (Figure). The slope of observed and predicted death using the ACC model, however, is markedly steeper, indicating a significant overprediction of mortality in each risk decile. In the higher risk deciles, the Michigan model underpredicted mortality.
|
With univariate logistic regression models, the association between each of the risk scores and in-hospital mortality was similar across the 5 models, with a 1-point increase in the calculated score associated with an
3-fold increase in risk of in-hospital mortality among NHLBI Registry patients (Table 3). Model discrimination measured by the C statistic ranged between 0.84 to 0.89, and there was little departure in model fit on the basis of the Hosmer-Lemeshows goodness-of-fit statistic (P>0.05). The area under the ROC curve was significantly lower (P
0.01 for each comparison) for the Cleveland Clinic model compared with the NY State, the ACC, and the Northern New England models.
|
| Discussion |
|---|
|
|
|---|
Variables used in models of PCI outcome must be easily obtained, objective, and have a high degree of observed correlation on repeated measurements, and model fit should be high.12,13 Other important considerations include assessment of the validity of the model in patient groups other than those for whom the model was developed and documentation of the relevance of the model when technology used to treat patients involved has changed substantially.
Before this report, external validation of in-hospital mortality models has been evaluated using single-site data. The Northern New England and Cleveland Clinic models were validated using data from 1476 consecutive high-risk PTCA patients6 in whom the in-hospital mortality was 3.4%. Multivariate regression analyses indicated that both models, when fit to the external data set, had excellent discrimination and were quite accurate in predicting in-hospital mortality. The NY state in-hospital model was found to predict procedural mortality accurately in 3761 consecutive patients treated with stents at a single center.3 Again, there was no statistical difference between observed and predicted in-hospital mortality rates, and the model discrimination on the basis of the ROC curve was high.
Although all 5 mortality models2,812 incorporated similar demographic, existing comorbidities (cardiogenic shock, renal disease, congestive heart failure), and certain procedural variables, there were some differences. All in-hospital mortality models with the exception of NY State included lesion class and/or complexity variables, which are often subjective and may not have a high degree of correlation on repeated sampling. Specific lesion location, adjunctive therapy (thrombolytics), and modern era device use variables were also integrated into the Northern New England, Cleveland Clinic, and the ACC models. These models were developed using widely different sample sizes, 2 of which had >50 000 procedures, whereas the others ranged between 10 796 and 15 331 procedures. The number of explanatory variables significantly associated with in-hospital mortality and their respective magnitude of effect may be influenced by sample size. For missing data, imput values, most frequently with ejection fraction, were used in model development in the Northern New England, ACC, and Michigan groups, which could have introduced misclassification bias. There was no information available on treatment of missing values for either the NY State or Cleveland Clinic models. The in-hospital mortality rate reported by each study was fairly consistent and ranged between 0.9% (NY State) and 1.6% (Michigan), despite case mix variations, prevalence of risk factors, and type of PCI performed.
We can only speculate as to why the Michigan model12 somewhat underestimated and the ACC model10 significantly overpredicted in-hospital mortality. The NHLBI Dynamic Registry did not collect data on history of cardiac arrest, a strong risk factor (odds ratio=3.65) in the Michigan model of procedural mortality. Although the prevalence of cardiac arrest may be low, the probability of death based on this model for such patients would actually be higher than the value used in this analysis. Another potential explanation for the underestimation of observed mortality involves creatinine levels, which was also strongly associated with mortality (odds ratio=5.5). We substituted history of renal disease for creatinine >1.5 mg/dL; this may have led to the misclassification of patients who did not report a history renal disease but who had a creatinine >1.5 mg/dL.
The results generated using the ACC model are more puzzling. This model predicts that patients with no risk factors (those included in their published model) will have a predicted death rate of
1.1% (Appendix 2). This is a surprisingly high number given that the observed mortality rate among the 100 253 ACC procedures (both low and high risk patients) was 1.4%. Although there are some notable patient differences between the NHLBI and ACC registries with respect to reason for revascularization (unstable angina: NHLBI, 47%; ACC, 62%; acute myocardial infarction: NHLBI, 10%; ACC, 17%), the Northern New England model included a large proportion of patients with unstable angina (73%), and 13% of PCI patients in Michigan were experiencing an acute myocardial infarction. The baseline model (no risk factors) predicted mortality rate in the Northern New England and Michigan models were 0.05% and 0.07%, respectively. Differences in underlying patient characteristics in the ACC model, therefore, do not seem to account for all of the overprediction. The ACC model will very likely overestimate predicted in-hospital mortality in any population that includes a high proportion of low and medium risk patients, as was seen in the NHLBI Dynamic Registry. Although these results cannot be explained fully, we applied an unpublished in-hospital mortality model developed using a later version of the ACC data (n=78 850 procedures) to the NHLBI Registry, and this new model predicted 51 deaths (1.1%; 95% CI, 0.9% to 1.4%; R. E. Shaw, PhD, unpublished data, October, 2002). Consistent with the published ACC model, the new model included the variables salvage PCI (versus elective) and intra-aortic balloon pump, which were not collected in the NHLBI Registry. Both of these variables were strongly associated with mortality; this could lead to an underestimation of predicted in-hospital mortality using this model.
The present report further extends the validity and relevance of the NY State, the Northern New England, and the Cleveland Clinic models when applied to a multicenter external data source of patients undergoing PCI in the stent era. The NY State and Cleveland Clinic models developed in patients treated with conventional angioplasty remain robust, even though 74% of the NHLBI Dynamic Registry patients received a stent and 27% received a glycoprotein IIb/IIIa receptor inhibitor. The Northern New England model included patients receiving new devices. Despite advances in technology, which introduces the potential to treat successfully more complex lesions and reduce nonfatal complications, the pre- and early stent-era models continue to be applicable in the modern era. Recent technological advances do not seem to improve mortality resulting from underlying comorbid conditions, left ventricular dysfunction, or advanced untreatable disease.
Limitations
The NHLBI Dynamic Registry involves experienced interventional cardiology centers with broad exposure to a wide range of patients. The excellent predictive nature of several in-hospital mortality models using these Dynamic Registry centers may not be completely relevant to other centers, although the NY State and Northern New England models were developed in patients treated at variety of centers. Average risk scores calculated for most of the models (NY State, ACC, Northern New England, and Michigan) might be underestimated in the Dynamic Registry patients because data on several variables were not collected. Finally, imputation of ejection fraction may have led to some misclassification.
Conclusions
The NY State, the Northern New England, and the Cleveland Clinic mortality models, developed in the pre- and early-stent eras of interventional cardiology, remain relevant in the current era of PCI and can be used to predict in-hospital death. Accordingly, they continue to be useful for risk stratification and outcome assessment.
| Appendix 1 |
|---|
|
|
|---|
ACC
Northern New England
2.0 mg/dL
Michigan
Cleveland Clinic Foundation
| Appendix 2 |
|---|
|
|
|---|
NY State Model: 50 000x(e-9.9128)/(1+e-9.9128)
2.5 patients or 0.005%
ACC Model: 50 000x(e-4.464)/(1+e-4.464)
569 patients or 1.1%.
Received November 15, 2002; revision received February 7, 2003; accepted February 7, 2003.
| References |
|---|
|
|
|---|
2. OConnor GT, Malenka DJ, Quinton H, et al. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 19941996. J Am Coll Cardiol. 1999; 34: 681691.
3. Holmes DR, Berger PB, Garratt KN, et al. Application of the New York State PTCA mortality model in patients undergoing stent implantation. Circulation. 2000; 102: 517522.
4. Kimmel SE, Berlin JA, Storm BL, et al. Development and validation of a simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice. J Am Coll Cardiol. 1995; 26: 931938.[Abstract]
5. Block PC, Peterson EC, Krone R, et al. Identification of variables needed to risk adjust outcomes of coronary interventions: evidence-based guidelines for efficient data collection. J Am Coll Cardiol. 1998; 32: 275282.
6. Moscucci M, OConnor GT, Ellis SG, et al. Validation of risk adjustment models for in-hospital percutaneous transluminal coronary angioplasty mortality on an independent data set. J Am Coll Cardiol. 1999; 34: 692697.
7. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361387.[CrossRef][Medline] [Order article via Infotrieve]
8. Hannan EL, Racz M, Ryan TJ, et al. Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA. 1997; 279: 892898.
9. Hannan EL, Arani DJ, Johnson LW, et al. Percutaneous transluminal coronary angioplasty in New York State: risk factors and outcomes. JAMA. 1992; 268: 30923097.
10. Shaw RE, Anderson V, Brindis RG, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 19982000. J Am Coll Cardiol. 2002; 39: 11011112.
11. Ellis SG, Weintraub W, Holmes DR, et al. Relation of operator volume and experience to procedural outcome of percutaneous coronary revascularization at hospitals with high interventional volumes. Circulation. 1997; 96: 24792484.
12. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation. 2001; 104: 263268.
13. Rihal CS, Grill DE, Bell MR, et al. Prediction of death after percutaneous coronary interventional procedures. Am Heart J. 2000; 139: 10321038.[CrossRef][Medline] [Order article via Infotrieve]
14. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 19851986: the heart, lung, and blood institute registries. Circulation. 2000; 102: 29452951.
15. Laskey WK, Williams DO, Vlachos HA, et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart Lung and Blood Institute Dynamic Registry. Am J Cardiol. 2001; 87: 964969.[CrossRef][Medline] [Order article via Infotrieve]
16. Hosmer DW Jr, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989.
This article has been cited by other articles:
![]() |
K. M. Kenney, M. C. Marzo, N. R. Ondrasik, and T. Wisenbaugh Percutaneous Coronary Intervention Outcomes in a Low-Volume Center: Survival, Stent Thrombosis, and Repeat Revascularization Circ Cardiovasc Qual Outcomes, November 1, 2009; 2(6): 671 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. S. Resnic and F. G.P. Welt The public health hazards of risk avoidance associated with public reporting of risk-adjusted outcomes in coronary intervention. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 825 - 830. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Holmes Jr and D. O. Williams Catheter-Based Treatment of Coronary Artery Disease: Past, Present, and Future Circ Cardiovasc Interv, August 1, 2008; 1(1): 60 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Singh, B. J. Gersh, S. Li, J. S. Rumsfeld, J. A. Spertus, S. M. O'Brien, R. M. Suri, and E. D. Peterson Mayo Clinic Risk Score for Percutaneous Coronary Intervention Predicts In-Hospital Mortality in Patients Undergoing Coronary Artery Bypass Graft Surgery Circulation, January 22, 2008; 117(3): 356 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. King III, T. Aversano, W. L. Ballard, R. H. Beekman III, M. J. Cowley, S. G. Ellis, D. P. Faxon, E. L. Hannan, J. W. Hirshfeld Jr, A. K. Jacobs, et al. ACCF/AHA/SCAI 2007 Update of the Clinical Competence Statement on Cardiac Interventional Procedures: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures) J. Am. Coll. Cardiol., July 3, 2007; 50(1): 82 - 108. [Full Text] [PDF] |
||||
![]() |
A D Grayson, R K Moore, M Jackson, S Rathore, S Sastry, T P Gray, I Schofield, A Chauhan, F F Ordoubadi, B Prendergast, et al. Multivariate prediction of major adverse cardiac events after 9914 percutaneous coronary interventions in the north west of England Heart, May 1, 2006; 92(5): 658 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wu, E. L. Hannan, G. Walford, J. A. Ambrose, D. R. Holmes Jr, S. B. King III, L. T. Clark, S. Katz, S. Sharma, and R. H. Jones A Risk Score to Predict In-Hospital Mortality for Percutaneous Coronary Interventions J. Am. Coll. Cardiol., February 7, 2006; 47(3): 654 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Udelson and H. P. Selker Quantitative instruments for predicting risk ... and benefit J. Am. Coll. Cardiol., March 1, 2005; 45(5): 730 - 732. [Full Text] [PDF] |
||||
![]() |
C. R. Narins, A. M. Dozier, F. S. Ling, and W. Zareba The Influence of Public Reporting of Outcome Data on Medical Decision Making by Physicians Arch Intern Med, January 10, 2005; 165(1): 83 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Singh, R. J. Lennon, D. Darbar, B. J. Gersh, D. R. Holmes Jr, and C. S. Rihal Effect of Peripheral Arterial Disease in Patients Undergoing Percutaneous Coronary Intervention With Intracoronary Stents Mayo Clin. Proc., September 1, 2004; 79(9): 1113 - 1118. [Abstract] [PDF] |
||||
![]() |
P. C. Lee, A. S. Kini, C. Ahsan, E. Fisher, and S. K. Sharma Anemia is an independent predictor of mortality after percutaneous coronary intervention J. Am. Coll. Cardiol., August 4, 2004; 44(3): 541 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. O'Neill and S. R. Dixon The year in interventional cardiology J. Am. Coll. Cardiol., March 3, 2004; 43(5): 875 - 890. [Full Text] [PDF] |
||||
![]() |
D. E. Cutlip, K. K. L. Ho, R. E. Kuntz, and D. S. Baim Risk assessment for percutaneous coronary intervention: our version of the weather report? J. Am. Coll. Cardiol., December 3, 2003; 42(11): 1896 - 1899. [Full Text] [PDF] |
||||
![]() |
D. R. Holmes Jr Risk Stratification and Interventional Cardiology: Robert L. Frye Lecture Mayo Clin. Proc., December 1, 2003; 78(12): 1507 - 1518. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |